秋水仙碱在急性冠脉综合征中的系统评价与荟萃分析
结果显示秋水仙碱可降低复发性ACS和不稳定心绞痛发生率,但全因死亡、心血管死亡和不良心血管事件无显著差异,低剂量可能获益且胃肠道症状与高剂量相关。
要点
- 秋水仙碱降低复发性ACS(RR 0.41)和不稳定心绞痛(RR 0.27)。
- 全因死亡、心血管死亡及不良心血管事件无显著差异。
- 0.5 mg/日可能降低不良心血管事件,高剂量增加胃肠道症状。
核心结论
- 低剂量秋水仙碱可能减少ACS患者复发性缺血事件,但证据因异质性和长期数据有限而不确定。
主要发现
- 秋水仙碱降低复发性ACS(RR 0.41,95%CI 0.19-0.92;p=0.03;I²=55%)和不稳定心绞痛(RR 0.27,95%CI 0.11-0.63;p<0.01;I²=0%)。
- 全因死亡(RR 0.95,95%CI 0.79-1.14;I²=12%)、心血管死亡(RR 1.03,95%CI 0.82-1.30;I²=0%)和不良心血管事件(RR 0.77,95%CI 0.59-1.01;p=0.05;I²=58%)无显著差异。
- 亚组分析提示剂量依赖性效应,0.5 mg/日可能降低不良心血管事件(RR 0.63,95%CI 0.45-0.88;I²=41%),但更高剂量增加胃肠道症状。
关键数值与推荐
- 复发性ACS:RR 0.41(95%CI 0.19-0.92;p=0.03;I²=55%)。
- 不稳定心绞痛:RR 0.27(95%CI 0.11-0.63;p<0.01;I²=0%)。
- 全因死亡:RR 0.95(95%CI 0.79-1.14;I²=12%)。
- 心血管死亡:RR 1.03(95%CI 0.82-1.30;I²=0%)。
- 不良心血管事件:RR 0.77(95%CI 0.59-1.01;p=0.05;I²=58%)。
临床怎么用
- 低剂量秋水仙碱(0.5 mg/日)可考虑用于ACS后减少复发性缺血事件,但需权衡胃肠道不良反应。
- 高剂量秋水仙碱增加胃肠道症状,不建议采用。
- 女性患者的安全性和有效性及最佳剂量需进一步研究。
局限性
- 证据因异质性(如I²=55%和58%)而不确定。
- 长期数据有限。
- 女性患者的安全性和有效性及最佳剂量尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute coronary syndrome (ACS) is a global leading cause of morbidity, with residual inflammation contributing to recurrent events. Colchicine has been proposed as an adjunct therapy, but its efficacy remains uncertain. METHODS: We performed a systematic review and meta-analysis. PubMed, Embase and Cochrane databases were searched for randomised controlled trials (RCTs) data comparing colchicine versus placebo in ACS. Risk ratio (RR) and mean difference with 95% CIs were computed for binary and continuous outcomes, respectively. Primary outcomes were adverse cardiovascular events (ACEs), mortality and safety. Random-effects models were used for pooled estimates. RESULTS: Seventeen RCTs comprising 14 794 patients were included, of whom 7390 (50%) were randomised to colchicine. The mean patient age across the studies ranged from 54 to 63 years, in a follow-up period ranging from 5 days to 12 months. Colchicine reduced the incidence of recurrent ACS (RR 0.41, 95% CI 0.19 to 0.92; p=0.03; I²=55%) and unstable angina (RR 0.27, 95% CI 0.11 to 0.63; p<0.01; I²=0%). No meaningful differences were observed in all-cause mortality (RR 0.95, 95% CI 0.79 to 1.14; I²=12%), cardiovascular death (RR 1.03, 95% CI 0.82 to 1.30; I²=0%) or ACE (RR 0.77, 95% CI 0.59 to 1.01; p=0.05; I²=58%). Subgroup analyses suggested a dose-dependent effect, with 0.5 mg/day potentially reducing ACE (RR 0.63, 95% CI 0.45 to 0.88; I²=41%), but higher doses increasing gastrointestinal symptoms. CONCLUSION: Low-dose colchicine may reduce recurrent ischaemic events in ACS, but evidence remains uncertain due to heterogeneity and limited long-term data. Safety and efficacy in women and optimal dosing require further investigation. TRIAL REGISTRATION NUMBER: CRD42024627348.
引用
- Huntermann, Peres de Oliveira, Barbosa, et al. Colchicine in acute coronary syndromes: a systematic review and meta-analysis of randomised controlled trials. Heart. 2026. PMID: 40379469. doi:10.1136/heartjnl-2025-325826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。